Skip to Content

Pegvisomant Disease Interactions

There are 2 disease interactions with pegvisomant:

Moderate

Pegvisomant (applies to pegvisomant) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Pegvisomant is an analog of human growth hormone (GH) that selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. The use of growth hormones opposes the effects of insulin on carbohydrate metabolism by decreasing insulin sensitivity; therefore, glucose intolerance may improve in some patients treated with pegvisomant. Diabetic patients should be monitored closely, and the doses of anti-diabetic drugs may be reduced as necessary to avoid hypoglycemia. Blood glucose levels should be evaluated as appropriate.

Moderate

Pegvisomant (applies to pegvisomant) liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Asymptomatic, transient elevations in transaminases up to 15 times ULN have been observed in patients treated with pegvisomant. Baseline serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL), and alkaline phosphatase (ALP) levels should be obtained prior to initiating therapy with pegvisomant. Care should be exercised when using this agent in patients with liver dysfunction and its use should be used in accordance with the information presented in the manufacturer prescribing information with respect to liver test abnormalities.

Pegvisomant drug interactions

There are 71 drug interactions with pegvisomant

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.